
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
AST’s VP of Business Development, Josh Russell, discusses the company’s impact on the pharmaceutical industry using innovative fill/finish equipment.
Watch the video and learn more:






